Zobrazeno 1 - 10
of 248
pro vyhledávání: '"Yasuteru Kondo"'
Autor:
Junji Furuse, Namiki Izumi, Kenta Motomura, Yoshitaka Inaba, Yoshio Katamura, Yasuteru Kondo, Kazuhisa Yabushita, Katsuaki Motoyoshi, Masatoshi Kudo
Publikováno v:
Drugs - Real World Outcomes, Vol 10, Iss 2, Pp 195-205 (2023)
Abstract Background Lenvatinib was approved for use in unresectable hepatocellular carcinoma (uHCC) in Japan in 2018. Patients with diverse clinical characteristics receive lenvatinib treatment in clinical practice. Thus, it is crucial to evaluate th
Externí odkaz:
https://doaj.org/article/1586272cd8f54a5590c0cca0a2b18019
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Alternative treatment modalities are necessary because of the low response rates and unsuitability of molecular-targeted agents (MTA) and/or immune checkpoint inhibitors (iCIs) in HCC patients. Therefore, we analyzed whether drug-eluting bea
Externí odkaz:
https://doaj.org/article/2c2f6b43b78c4decbf6542cdde471b79
Autor:
Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, Toru Ishikawa, Yoshitaka Inaba, Naoki Morimoto, Hiroshi Aikata, Nobukazu Tanabe, Yoshiyuki Wada, Yasuteru Kondo, Masahiro Tsuda, Kazuhiko Nakao, Takanori Ito, Tetsuya Hosaka, Yusuke Kawamura, Teiji Kuzuya, Shunsuke Nojiri, Chikara Ogawa, Hironori Koga, Keisuke Hino, Masafumi Ikeda, Michihisa Moriguchi, Takashi Hisai, Kenichi Yoshimura, Junji Furuse, Yasuaki Arai
Publikováno v:
Liver Cancer (2023)
Background: Transarterial chemoembolization (TACE) is the standard treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC), but recurrence after TACE is common. The present phase II, prospective, multicenter, single-arm trial, th
Externí odkaz:
https://doaj.org/article/48f623fe69374965a18cf38cb68f57fa
Autor:
Yasuteru Kondo, Junichi Akahira, Tatsuki Morosawa, Yukihiro Toi, Akashi Endo, Hiroaki Satio, Mareyuki Endo, Shunichi Sugawara, Yasuhito Tanaka
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract It has been reported that various kinds of immune checkpoint inhibitors (iCIs) could induce immune-related liver damage. We should focus on the programmed cell death-receptor-1 (PD-1) antibody and non-small cell lung cancer (NSCLC) to analyz
Externí odkaz:
https://doaj.org/article/15e200a3a93d41609ec915336caefa62
Autor:
Chia-Lin Chen, Jeffrey Y. Huang, Chun-Hsiang Wang, Stanley M Tahara, Lin Zhou, Yasuteru Kondo, Joel Schechter, Lishan Su, Michael M C. Lai, Takaji Wakita, François-Loïc Cosset, Jae U Jung, Keigo Machida
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-17 (2017)
Infection of B cells by hepatitis C virus (HCV) is poorly understood, but is thought to result in lymphoproliferative disorders. Here, Chenet al. identify CD86 as co-receptor for lymphotropic HCV and show that HCV infection inhibits memory B-cell fun
Externí odkaz:
https://doaj.org/article/1991ac8957f64473b697653d17ea07e4
Autor:
Hiromasa Ohira, Atsushi Takahashi, Mikio Zeniya, Masanori Abe, Teruko Arinaga‐Hino, Satoru Joshita, Akinobu Takaki, Nobuhiro Nakamoto, Jong‐Hon Kang, Yoshiyuki Suzuki, Tsuyosi Sogo, Ayano Inui, Kazuhiko Koike, Kenichi Harada, Yasunari Nakamoto, Yasuteru Kondo, Takuya Genda, Koichi Tsuneyama, Tsuyoshi Matsui, Atsushi Tanaka
Publikováno v:
Hepatology Research. 52:571-585
Autor:
Kazuhiro Kozumi, Daisuke Motooka, Yoshihiro Kamada, Tomohide Tatsumi, Ryotaro Sakamori, Yukinori Yamada, Simon Cockell, Hiroki Murai, Eiichi Morii, Olivier Govaere, Tetsuo Takehara, Yasuteru Kondo, Ryoko Yamada, Yuki Tahata, Ann K. Daly, Hayato Hikita, Naruyasu Kakita, Takahiro Kodama, Quentin M. Anstee, Sadatsugu Sakane
Publikováno v:
Hepatology (Baltimore, Md.)
BACKGROUND AND AIMS: NAFLD is the most common liver disease worldwide. NASH, the progressive form of NAFLD, and advanced fibrosis are associated with poor outcomes. We searched for their noninvasive biomarkers. APPROACH AND RESULTS: Global RNA sequen
Autor:
Yasuteru Kondo, Tooru Shimosegawa
Publikováno v:
International Journal of Molecular Sciences, Vol 16, Iss 2, Pp 3307-3322 (2015)
The adaptive immune system, including type1 helper T cells (Th1 cells), cytotoxic T lymphocytes (CTLs), and dendritic cells (DCs), plays an important role in the control of hepatitis B virus (HBV). On the other hand, regulatory T cells (Tregs) and my
Externí odkaz:
https://doaj.org/article/d3015a0065104b2fbd7cdc2f9c0914b7
Autor:
Koji Ogawa, Masaru Enomoto, Yasuteru Kondo, Tomomitsu Matono, Syuichi Sato, Mika Horino, Kiyoaki Ito, Atsushi Suetsugu, Masaaki Korenaga, Isao Sakaida, Isao Hidaka, Jun Inoue
Publikováno v:
Internal Medicine. 60:337-343
Objective Persistent hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are major causative factors of hepatic cirrhosis and hepatocellular carcinoma. However, the development of antiviral treatment has enabled their suppression. Therefor
Autor:
Takayuki Tokunaga, Masakuni Tateyama, Yasuteru Kondo, Satoshi Miuma, Shiho Miyase, Kentaro Tanaka, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Yoko Yoshimaru, Katsuya Nagaoka, Takehisa Watanabe, Hiroko Setoyama, Kotaro Fukubayashi, Motohiko Tanaka, Yasuhito Tanaka
Publikováno v:
Cancers; Volume 15; Issue 5; Pages: 1568
We retrospectively evaluated the impact of therapeutic modifications of atezolizumab (Atezo) plus bevacizumab (Bev) therapy (Atezo/Bev), including the interruption or discontinuation of both Atezo and Bev, and the reduction or discontinuation of Bev,